Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity

FEMS Immunology and Medical Microbiology

Volumn 51, Issue 1, 2007, Pages 201-211

  Lee, Jae Chul ^a,f   Yokoyama, Teruhiko ^a   Hwang, Hyun Jung ^a,b   Arimitsu, Hideyuki ^c   Yamamoto, Yumiko ^a   Kawasaki, Makiko ^a   Takigawa, Tomoko ^a   Takeshi, Kouichi ^d   Nishikawa, Atsushi ^e   Kumon, Hiromi ^a   Oguma, Keiji ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^e TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^f Medy Tox Inc   (South Korea)

Author keywords

Clinical application; Clostridium botulinum; Dystonia; Neurotoxin

Indexed keywords

ALBUMIN; BOTULINUM TOXIN A; HEMAGGLUTININ; LEVOFLOXACIN; NEUROTOXIN; TREHALOSE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM TYPE A; CONTROLLED STUDY; CYSTOMETRY; CYTOTOXICITY; DETRUSOR DYSSYNERGIA; DRUG PURIFICATION; FEMALE; HUMAN; HUMAN CELL; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PH MEASUREMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; URINE INCONTINENCE;

ADULT; AGED; ANIMALS; BOTULINUM TOXIN TYPE A; CELL LINE; DRUG STABILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXINS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 34548584055     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00301.x     Document Type: Article

References (20)

1. Arimitsu H, Inoue K, Sakaguchi Y, Lee JC, Fujinaga Y, Watanabe T, Ohyama T, Hirst R Oguma K (2003) Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patient with dystonia. Infect Immun 71 : 1599 1603.
2. Dykstra DD, Sidi AA, Scott AB, Pagel JM Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 : 919 922.
3. Gao B Tsan MF (2003) Recombinant human heat shock protein 60 does not induce the release of tumor necrosis factor from murine macrophages. J Biol Chem 25 : 22523 22529.
4. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A Gleason D (1999) Standardization of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International continence society subcommittee on standardization of terminology of pressure-flow studies. Neurourol Urodyn 16 : 1 18.
5. Haan LD, Hearn AR, Rivett AJ Hirst TR (2002) Enhanced delivery of enogenous peptides into the class I antigen processing and presentation pathway. Infect Immun 70 : 3249 3258.
6. Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K Oguma K (1996) Molecular composition of Clostridium botulinum type A PTXs. Infect Immun 64 : 1589 1594.
7. Jankovic J Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324 : 1186 1194.
8. Kira S, Taketa K, Nogami Y Hayatsu H (1995) A simplified technique for monitoring mutagenicity and benzo(a)pyrene content in mussels and their ambient water. Environ Toxicol Water Qua1 10 : 167 172.
9. Lee JC, Yokota K, Arimitsu H, Hwang HJ, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T Oguma K (2005) Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiology 151 : 3739 3747.
10. Lew MF, Brashear A Factor S (2000) The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 55 : S29 S35.
11. Oguma K, Inoue K, Fujinaga Y, Yokota K, Watanabe T, Ohyama T, Takeshi K Inoue K (1999) Structure and function of Clostridium botulinum PTX. J Toxicol-Toxin Rev 18 : 17 34.
12. Radziszewski P, Dobronski P Borkowski A (2001) Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A-A pilot study. Neurourol Urodyn abstract 20 : 410 412.
13. Sakaguchi G, Kozaki S Ohishi I (1984) Structure and function of botulinum toxins. Bacterial Protein Toxins (Alouf JE, Fehrenbach FJ, Freer JH Jeljaszewicz J, eds), pp. 435 443. Academic Press, London, UK.
14. Schmid DM, Sauermann P, Werner M et al 2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 : 177 185.
15. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 : 692 697.
16. ® detrusor hyperreflexia study team: botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 : 196 200.
17. Smith C, Nishiguchi J, O'Leary M, Yoshimura N Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65 : 37 41.
18. Sugii S Sakaguchi G (1975) Molecular construction of Clostridium botulinum type A toxins. Infect Immun 12 : 1262 1270.
19. Wagner TH, Patrick DL, Bavendam TG, Martin ML Buesching DP (1996) Quality of life of persons with urinary incontinence: development of a new measure. Urology 47 : 67 71.
20. Yahagi T, Nagao M, Seino Y, Matsushima T Sugimura T (1977) Mutagenicities of N-nitrosamines on salmonella. Mutat Res 48 : 121 129.